Nabriva names chief medical officer
This article was originally published in Scrip
Nabriva Therapeutics, a clinical-stage biopharmaceutical company developing novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, has named Elyse Seltze chief medical officer. Dr Seltzer assumes the role from Dr William Prince, who will transition to senior vice-president of clinical science. Dr Seltzer joins Nabriva from GlaxoSmithKline, where she was vice-president of global clinical sciences and operations.